VGN-R08b
/ Shanghai Vitalgen BioPharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 18, 2026
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations
(clinicaltrials.gov)
- P1/2 | N=17 | Not yet recruiting | Sponsor: Shanghai Vitalgen BioPharma Co., Ltd.
New P1/2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease • GBA1
1 to 1
Of
1
Go to page
1